Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease ...

In recent trading, Annovis Bio Inc (ANVS) stock price has shown some volatility, fluctuating -0.59% over the last five trades and -13.2 ...

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is developing innovative therapies that ...

Annovis Bio (ANVS) stock slipped after the company said the FDA accepted its updated protocol for a Phase 3 trial for its ...

Annovis Bio (NYSEMKT:ANVS) just reported results for the first quarter of 2024. Annovis Bio reported earnings per share of -72 cents. This was above the analyst estimate for EPS of -80 cents.

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Annovis Bio (ANVS – Research Report), retaining the price target of ...

MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company ...

Shares of Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) have received an average rating of “Buy” from the seven analysts that are covering the company, MarketBeat reports.One equities ...

MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased ...